Friday, July 31, 2009

Amgen Statement on the House Energy & Commerce Committee’s Approval of an Amendment to Create a Biosimilars Pathway

The following statement was issued today by Amgen on the passage of the Eshoo-Inslee-Barton amendment to the House Energy & Commerce Committee’s health care reform legislation.

The strong bipartisan support in the Energy and Commerce Committee for a fair and balanced pathway for the approval of biosimilars is a win for patients. The amendment introduced by Representatives Eshoo, Inslee and Barton and overwhelmingly approved by the Committee strikes a necessary balance in allowing access to safe and effective biosimilar medicines for patients, and providing fair incentives for the discovery of new medicines for serious diseases.

Read the rest of this entry

Posted in Company Statements

Monday, July 27, 2009

Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)

Amgen to Retain Full Rights for Denosumab in the United States and Canada and for Oncology Indications in Europe GlaxoSmithKline Will Commercialize Denosumab for PMO and Oncology in Emerging Markets

THOUSAND OAKS, Calif. and LONDON – July 27 – Amgen (Nasdaq: AMGN) andGlaxoSmithKline (GSK) today announced a collaboration in which the companies will share commercialization of Amgen’s monoclonal antibody denosumab for postmenopausal osteoporosis (PMO) inEurope, Australia, New Zealand and Mexico once the product is approved in these countries. Amgen will commercialize the drug for PMO and oncology in the United States (U.S.) and Canada and for all oncology indications in Europe and specified markets.

Read the rest of this entry

Posted in Press Releases, Pipeline News

Monday, July 27, 2009

Amgen's Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To $1.29

Second Quarter 2009 Revenue Decreased 1 Percent to $3.7 Billion Second Quarter 2009 GAAP Earnings Per Share Increased 49 Percent to $1.25 2009 Total Revenue Trending Towards Upper End of Current Guidance Range of $14.4-$14.8 Billion 2009 Adjusted Earnings Per Share Guidance Range of $4.55-$4.75 Raised to $4.80-$4.95

THOUSAND OAKS, Calif. –July 27 – Amgen (Nasdaq: AMGN) reported adjusted earnings per share (EPS) of $1.29 for the second quarter of 2009, an increase of 13 percent compared to$1.14 for the second quarter of 2008. Adjusted net income increased 6 percent to $1,311 million in the second quarter of 2009 compared to $1,235 million in the second quarter of 2008.

Read the rest of this entry

Posted in Press Releases

Monday, July 20, 2009

Amgen Scholars Discover Their Potential During Summer Science Research Program and National Symposium

THOUSAND OAKS, Calif. – July 20, 2009 – From July 18-20, more than 260 of the country’s brightest undergraduate students met at UCLA for the third annual Amgen Scholars U.S. Symposium designed to bring together program participants and help them apply their science research experiences into future science careers.

Read the rest of this entry

Posted in Philanthropy, Press Releases

Friday, July 17, 2009

Amgen Announces KRAS Safety Update to U.S. Prescribing Information for Vectibix(R) (Panitumumab)

Class Labeling Recognizes KRAS as a Predictive Biomarker for anti-EGFr Antibody Monotherapy in Metastatic Colorectal Cancer

Results from First Pivotal Trials Prospectively Evaluating KRAS Utility in Combination Therapy Expected In Third Quarter 2009

 THOUSAND OAKS, Calif., July 17 /PRNewswire-FirstCall/—Amgen Inc. (Nasdaq: AMGN) today announced the U.S. Food and Drug Administration (FDA) has approved revisions to the U.S. prescribing information for the epidermal growth factor receptor (EGFr) class of antibodies, including Vectibix (panitumumab). This decision follows the FDA’s December 2008 Oncologics Drugs Advisory Committee (ODAC) meeting where the clinical utility of the KRAS gene as a predictive biomarker in patients with metastatic colorectal cancer (mCRC) treated with anti-EGFr antibody was discussed.

Read the rest of this entry

Posted in Press Releases, Product News